Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Principles of Disease Surveillance01:26

Principles of Disease Surveillance

Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integration of geriatric assessment-guided care plan modifications and interventions into clinical paths of older adults with cancer (GORILLA): a feasibility approach.

European geriatric medicine·2026
Same author

AI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose system.

Journal of medical systems·2026
Same author

Pre-Pectoral Breast Reconstruction after Mastectomy: Current Evidence, Knowledge Gaps, and Rationale for the I-PREPARE EUBREAST-11R Trial.

Breast care (Basel, Switzerland)·2026
Same author

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
Same author

Training and Subjective Confidence in CTG Interpretation in Germany: A National Cross-Sectional Survey.

Journal of multidisciplinary healthcare·2026
Same author

[Post-treatment care for breast cancer].

MMW Fortschritte der Medizin·2026

Related Experiment Video

Updated: May 10, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K

Will Minimal Residual Disease Monitoring Be Part of Routine Surveillance?

Kerstin Pfister1, Henning Schäffler1, Sophia Huesmann1

  • 1Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.

Oncology Research and Treatment
|February 25, 2025
PubMed
Summary

Circulating tumor DNA (ctDNA) shows promise for early breast cancer (BC) recurrence detection, offering a potential new window for treatment. While ctDNA is a reliable prognostic biomarker, more research is needed to confirm survival benefits from ctDNA-guided surveillance.

Keywords:
Breast cancerCirculating tumor DNALiquid biopsiesSurveillance

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Related Experiment Videos

Last Updated: May 10, 2026

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.1K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Clinical Trials

Background:

  • Current breast cancer (BC) surveillance relies on outdated methods for detecting recurrence.
  • Existing surveillance protocols do not incorporate advancements in liquid biopsy technology, such as circulating tumor DNA (ctDNA).

Purpose of the Study:

  • To evaluate the role of ctDNA as a prognostic biomarker in early breast cancer surveillance.
  • To explore the potential of ctDNA-guided follow-up for improving patient outcomes.
  • To assess the therapeutic window offered by the detection of minimal or molecular residual disease (MRD).

Main Methods:

  • Utilizing tumor-informed and tumor-agnostic approaches for ctDNA detection.
  • Analyzing ctDNA's sensitivity and specificity in predicting clinical breast cancer recurrence.
  • Evaluating the lead time between ctDNA detection and overt relapse.

Main Results:

  • ctDNA detection accurately predicts clinical breast cancer recurrence.
  • The lead time between ctDNA detection and clinical recurrence signifies a stage of MRD.
  • ctDNA shows potential for both initiating early treatment and de-escalating therapy.

Conclusions:

  • ctDNA is a reliable prognostic biomarker for early breast cancer surveillance.
  • ctDNA-based surveillance and adjuvant therapies hold potential for improved patient outcomes.
  • Further clinical trials are necessary to establish a survival benefit and confirm ctDNA-guided follow-up as a new standard of care.